Targeting angiogenesis in an age of personalized medicine.
Department of Radiology, Brain Tumor Center of Excellence, Wake Forest University Health Sciences, Winston-Salem, NC, USA.
Gopi K
GK
Kota
Pushpender
P
Gupta
Jesse Marie
JM
Conyers
Akiva
A
Mintz
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D006801:Humans; D008279:Magnetic Resonance Imaging; D057054:Molecular Imaging; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D049268:Positron-Emission Tomography; D057285:Precision Medicine; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab